http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
갠지하시모토,Yuko Fujita,Mao Horio,Hiroko Hagiwara,Yuko Tanibuchi,Masaomi Iyo 대한정신약물학회 2010 CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE Vol.8 No.2
This study was undertaken to examine the effects of cilostazol, a selective inhibitor of type III phosphodiesterase (PDE), on hyperlocomotion and prepulse inhibition (PPI) deficits in mice after a single administration of the N-methyl-D-aspartate (NMDA)receptor antagonist dizocilpine. A single oral administration of cilostazol (0.1 and 0.3 mg/kg) significantly attenuated hyperlocomotion and PPI deficits in mice after the administration of dizocilpine (0.1 mg/kg, subcutaneously). This study suggests that cilostazol may have antipsychotic activity in animal models of schizophrenia. Therefore, cilostazol may be a potential therapeutic drug for schizophrenia, given that cilostazol has been safely used throughout the world.
Effects of Cilostazol on Cognitive Deficits in Mice after Repeated Administration of Phencyclidine
갠지하시모토,Yuko Fujita,Tamaki Ishima,Mao Horio,Hiroko Hagiwara,Yuko Tanibuchi,Masaomi Iyo 대한정신약물학회 2010 CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE Vol.8 No.1
Objective : To examine the effects of cilostazol, a selective inhibitor of type III phosphodiesterase (PDE), on cognitive deficits in mice after repeated administration of the N-methyl-D-aspartate (NMDA) receptor antagonist phencyclidine (PCP). Methods:Saline (10 ml/kg/day) or PCP (10 mg/kg/day) were administered subcutaneously to mice for 10 days (once daily on days 1−5 and 8−12). Three days (day 15) after the final administration of saline or PCP, vehicle (0.5% carboxymethylcellulose)or cilostazol (0.3, 3, 10 or 30 mg/kg/day) were administered orally for 14 consecutive days (once daily on days 15−28). The novel object recognition test (NORT) was performed 24 hours (day 29) after the final administration. Results:In the NORT, PCP -induced cognitive deficits in mice were improved significantly by subsequent sub-chronic (14 days)administration of cilostazol (3, 10 or 30 mg/kg/day), but not by the lowest dose of cilostazol (0.3 mg/kg/day). Conclusion:This study suggests that cilostazol ameliorates PCP-induced cognitive deficits in mice. Therefore, it is likely that cilostazol has therapeutic potential for cognitive deficits in schizophrenia.